S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Podobne zapisy

• S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
  od: Cyrille Touzeau, i wsp.
  Wydane: (2023-08-01)
• S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS
  od: Nizar J Bahlis, i wsp.
  Wydane: (2023-08-01)
• P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1
  od: Leo Rasche, i wsp.
  Wydane: (2023-08-01)
• TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES
  od: NWCJV Donk, i wsp.
  Wydane: (2023-10-01)
• P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
  od: N. van de Donk, i wsp.
  Wydane: (2023-05-01)